Thirteen adult patients with FLT3-ITD mutated AML in morphological remission following allo-HSCT received one of two quizartinib dose levels at 40 mg/day (n = 7) and 60 mg/day (n = 6), administered orally for up to 24 months. The gene discussed is FLT3; the disease is acute myeloid leukemia.